Wednesday, July 8, 2026

Patent intelligence · US

US 12162948

Methods of engineering transferrin receptor binding polypeptides

granted A61KA61K38/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 42
Patent details — US 12162948

Quick answer

US 12162948 (Methods of engineering transferrin receptor binding polypeptides) is held by DENALI THERAPEUTICS INC.. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K38/00

More from DENALI THERAPEUTICS INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12378540

    Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

    DENALI THERAPEUTICS INC. · Expires Jul 31, 2045

    granted
  2. US 12358928

    Compounds, compositions and methods

    DENALI THERAPEUTICS INC. · Expires Jul 10, 2045

    granted
  3. US 12358896

    LRRK2 inhibitors and methods of making and using thereof

    DENALI THERAPEUTICS INC. · Expires Jul 10, 2045

    granted
  4. US 12240902

    Anti-TREM2 antibodies and methods of use thereof

    DENALI THERAPEUTICS INC. · Expires Feb 27, 2045

    granted
  5. US 12180211

    Compounds, compositions and methods

    DENALI THERAPEUTICS INC. · Expires Dec 26, 2044

    granted
  6. US 12129263

    Kinase inhibitors and uses thereof

    DENALI THERAPEUTICS INC. · Expires Oct 24, 2044

    granted
  7. US 11999750

    Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

    DENALI THERAPEUTICS INC. · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 12162948?

US 12162948 (Methods of engineering transferrin receptor binding polypeptides) is held by DENALI THERAPEUTICS INC.. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12162948?

DENALI THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 42 pharmaceutical patents for this assignee.

When does US 12162948 expire?

Our index shows an expiration date of Dec 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.